Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN358249 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Neurotrophic Tyrosine Kinase, Receptor, Type 1 (NTRK1) (pTyr791) antibody
- Antibody type
- Polyclonal
- Description
- Protein G Affinity Chromatography. Then, the antibody fraction is peptide affinity purified in a 2-step procedure with control and phosphorylated peptides. The phospho-specific antibody is eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
- Reactivity
- Human
- Host
- Rabbit
- Epitope
- pTyr791
- Vial size
- 0.4 mL
- Storage
- Store the antibody undiluted at 2-8°C for one month or (in aliquots) at-20°C for longer.
- Handling
- Avoid repeated freezing and thawing.
Submitted references Congenital insensitivity to pain with anhidrosis in Taiwan: a morphometric and genetic study.
Expression of activated TrkA protein in melanocytic tumors: relationship to cell proliferation and clinical outcome.
Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer.
TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma.
NGF activation of TrkA decreases N-myc expression via MAPK path leading to a decrease in neuroblastoma cell number.
Guo YC, Liao KK, Soong BW, Tsai CP, Niu DM, Lee HY, Lin KP
European neurology 2004;51(4):206-14
European neurology 2004;51(4):206-14
Expression of activated TrkA protein in melanocytic tumors: relationship to cell proliferation and clinical outcome.
Flørenes VA, Maelandsmo GM, Holm R, Reich R, Lazarovici P, Davidson B
American journal of clinical pathology 2004 Sep;122(3):412-20
American journal of clinical pathology 2004 Sep;122(3):412-20
Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer.
Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Pierotti MA, Greco A
Oncogene 2004 Sep 23;23(44):7436-40
Oncogene 2004 Sep 23;23(44):7436-40
TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma.
Tacconelli A, Farina AR, Cappabianca L, Desantis G, Tessitore A, Vetuschi A, Sferra R, Rucci N, Argenti B, Screpanti I, Gulino A, Mackay AR
Cancer cell 2004 Oct;6(4):347-60
Cancer cell 2004 Oct;6(4):347-60
NGF activation of TrkA decreases N-myc expression via MAPK path leading to a decrease in neuroblastoma cell number.
Woo CW, Lucarelli E, Thiele CJ
Oncogene 2004 Feb 26;23(8):1522-30
Oncogene 2004 Feb 26;23(8):1522-30
No comments: Submit comment
No validations: Submit validation data